HOSPITAL UNIVERSITARIO RUBER
Departamento
Kyoto University Hospital
Kioto, JapónPublicaciones en colaboración con investigadores/as de Kyoto University Hospital (5)
2024
-
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer
Future Oncology
-
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
ESMO Open, Vol. 9, Núm. 9
-
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Oncology, Vol. 25, Núm. 9, pp. 1231-1244
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
2020
-
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998